Drug intelligence / Profile preview

autologous CD34+ cell injection

Development stage: Preclinical
Lead developer: Foundation for Biomedical Research and Innovation at Kobe
Modality: Stem Cell Therapies → Cell Therapies
Administration: Intra-arterial

Overview

Autologous CD34+ cell injection is an experimental cell therapy being developed by the Foundation for Biomedical Research and Innovation at Kobe (FBRI) for the treatment of chronic ischemic stroke. The procedure involves isolating CD34-positive hematopoietic stem and progenitor cells from the patient's own body and delivering them via intra-carotid injection to the site of brain injury. These cells are hypothesized to promote vascular regeneration (angiogenesis) and provide neurotrophic support, thereby facilitating the repair of damaged neural tissue and improving functional outcomes in patients suffering from long-term effects of stroke. The program is currently in the preclinical stage of development.

Other names: Intra-carotid Autologous CD34+ Cell Injection

Beyond the preview

Go deeper on autologous CD34+ cell injection.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on autologous CD34+ cell injection.

Explore the full profile